Dry Eye News and Research

RSS
Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.
Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

FVCG portfolio companies selected to present research at Bio International 2015

FVCG portfolio companies selected to present research at Bio International 2015

Dry eye strikes most often in spring

Dry eye strikes most often in spring

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

EyePromise® eye vitamins offers education guide to promote awareness on AMD

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Study identifies correlations between BioLight's TeaRx diagnostic parameters and benchmark tests for dry eye syndrome

Study identifies correlations between BioLight's TeaRx diagnostic parameters and benchmark tests for dry eye syndrome

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

G-treeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome

G-treeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome